Handelsavisen
prelaunch
Companies ›Healthcare ›TISN.DH
TI
TISN.DH — — Pharmaceuticals

Tisn.Dh

—
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
2,06 %
Op margin
8,0 %
ROE
16,1 %
Net margin
5,3 %
Debt / equity
0,53
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

TISN.DH operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Business. TISN.DH operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
16,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TISN.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TISN.DH. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TISN.DH operates in the Pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    TISN.DH maintains a capital structure with a debt-to-equity ratio of 0.53, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.15, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited buffer. Free cash flow is negative at -331,752,870 BDT, which may signal pressure on liquidity and the need for external financing or operational improvements.

    Profitability metrics show a return on equity of 16.12% and a return on assets of 8.39%, both of which are strong indicators of efficient use of equity and assets. These figures suggest TISN.DH is performing well in terms of generating returns for shareholders and utilizing its asset base effectively.

    The company's revenue is concentrated in the Pharmaceuticals segment, with no disclosed geographic breakdown. This concentration may expose the company to sector-specific risks, such as regulatory changes or shifts in demand for pharmaceutical products.

    TISN.DH's growth trajectory is supported by a revenue of 11,883,593,710 BDT, with no specific growth rate provided. However, the company's capital expenditure of -981,496,790 BDT indicates significant investment in infrastructure or expansion, which could support future growth. The risk assessment highlights a key flag of negative net cash after subtracting total debt, which may affect the company's ability to fund operations without additional financing.

    Recent events, including the latest actual EPS of 20.27 BDT and revenue of 11,883,593,710 BDT, reflect the company's current financial performance. These figures are in line with analyst estimates, indicating that the company is meeting market expectations.

    Key takeaways
    • TISN.DH has a strong return on equity of 16.12%, indicating effective use of shareholder funds.
    • The company's debt-to-equity ratio of 0.53 suggests a balanced capital structure with moderate debt reliance.
    • Negative free cash flow of -331,752,870 BDT may indicate liquidity constraints or significant reinvestment in the business.
    • TISN.DH's revenue is concentrated in the Pharmaceuticals segment, which may expose it to sector-specific risks.
    • The company's capital expenditure of -981,496,790 BDT suggests ongoing investment in growth and infrastructure.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    —
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $3.93B
    Net cashⓘ
    -$2.07B
    Current ratioⓘ
    1.1
    Debt / equityⓘ
    0.5
    ROAⓘ
    8.4%
    ROEⓘ
    16.1%
    Cash conversionⓘ
    114.0%
    CapEx / revenueⓘ
    -8.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,0 %Above median
    Net Margin5,3 %Above median
    ROE16,1 %Above P75
    Capex / Rev-8,3 %Below median
    D/E0,53Below median
    Cash Conv1,14Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TISN.DH Market data — financials · 2026-05-29
    • Ibn Sina Pharmaceutical Industry PLC Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TISN.DHCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage